Navigation Links
Pharmaceuticals Market Access Taiwan 2013
Date:6/5/2013

DUBLIN, June 5, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/ms3fjr/pharmaceuticals) has announced the addition of a new report "Pharmaceuticals Market Access Taiwan" to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)


January 2013 will see implementation of Taiwan's second generation national health insurance law bringing important changes to the market for prescription medicines in one of Asia's booming tiger economies. The new drug pricing process will be modified and the importance of health technology assessment (HTA) reaffirmed. The Cross-Strait Co-operation Agreement on Medicine and Public Health Affairs with mainland China might be of even greater significance in the longer term as this potentially leads to progressive mutual recognition of clinical trial results. R&D companies active in Taiwan will then have easier access to the 1.3 billion consumers speaking the same language waiting just across the Strait.

Written with the understandable detail and objectivity you require, Pharmaceuticals Market Access Taiwan provides the answers needed for product introduction and life-cycle management in the sixth-largest market in Asia-Pacific:


- How the drug categorisation, launch pricing, price-volume agreement and price revision processes work, with data sources, timelines, examples and results.

- HTA policies by the Center for Drug Evaluation explained, with data sources, timelines, examples and results.

- Drug expenditure target as an alternative to biennial price cuts.

- Incomplete separation between prescribing and dispensing and the drug price gap.

- Impact of global budgets on pharmaceutical costs.

- Pay-for-performance incentives for prescribers.

- One of the world's best environments for rare disease management.

- Generic pricing and its relationship to product quality.

Key Features

Comprehensive:
Focusing on NHI reimbursement pricing but encompassing the IND to the PMS stages.

Detailed:
Over 30 tables, figures & case studies. Much not published in English before.

Up-to-date:
Based on face-to-face interviews with key market participants and data collection conducted in Taipei during September 2012. Includes brand-new local pharmacoeconomic study checklist.

Key Topics Covered:

Executive Summary
Acknowledgements

1. Market Introduction
2. Pharmaceutical Sector
3. Introductory Pricing of New Drugs
4. Health Technology Assessment
5. Price Revision
6. Generics
7. Demand-Side Controls
8. Payment of Providers
9. Distribution
10. Prospects for Change

List of Tables
List of Figures

Appendices
References 
Glossary of Abbreviations and Acronyms


Author

Donald Macarthur

For more information visit http://www.researchandmarkets.com/research/ms3fjr/pharmaceuticals

Source: Just Pharma Reports
Research and Markets
Laura Wood , Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716


Sector: Pharmaceuticals


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
(Date:5/29/2017)... TEL AVIV, Israel, May 29, 2017  Cellect Biotechnology ... of innovative technology which enables the functional selection of ... financial results for the first quarter ended March 31 ... pleased with our accomplishments in the first quarter of ... the first quarter, we announced the treatment of the ...
(Date:5/23/2017)... 23, 2017  Leaf Healthcare, recognized for developing ... for pressure ulcer prevention, will unveil its comprehensive ... Critical Care Nurses, National Teaching Institute and Critical ... The Leaf Patient Monitoring System is the first ... environment.  The system seamlessly tracks patient movement throughout ...
Breaking Medicine Technology:
(Date:6/22/2017)... ... ... Despite its pervasiveness, many physicians are unfamiliar with how best to treat ... practice. Now, however, a timely review has been published in the Journal of ... NeuP and educating preclinical scientists on its diagnosis and choice of treatment. , The ...
(Date:6/20/2017)... Murfreesboro, Tennessee (PRWEB) , ... June 20, 2017 ... ... chronic care services, announced today that Claritas Capital, a Nashville-based private equity firm, ... to accelerate our expansion plans for some time, and Claritas Capital offers the ...
(Date:6/20/2017)... ... June 20, 2017 , ... Hayes, Inc., ... a new eBook titled “ 5 Questions to Ask Before Entering the Maze ... the Genetic Test Evaluation (GTE) team, the book explores the various types of ...
(Date:6/20/2017)... ... 20, 2017 , ... AMC Health , the leading provider of proven ... trials market. Similar to its approach in demonstrating positive outcomes in the healthcare market, ... proving the value of eVisits to support virtual studies. , In a ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that puts ... NJ, Drs. Adam and Hal Kimowitz are currently accepting new patients at their practice ... can cause for some patients, which is why they offer the latest in modern ...
Breaking Medicine News(10 mins):